Maternal Factor V Leiden and placental thrombosis

Factor V Leiden is an inherited change in the F5 gene that makes factor V less responsive to activated protein C, one of the body’s natural anticoagulant mechanisms. Blood can therefore remain clotting-ready for longer than usual. Many carriers never develop a clot, while pregnancy can increase the clinical importance of the condition because normal changes in coagulation, reduced venous flow and placental circulation place extra demands on the maternal vascular system.

Placental thrombosis refers to clotting within placental vessels or areas of placental infarction, where tissue loses its blood supply. It can be associated with fetal growth restriction, pre-eclampsia, reduced fetal movements, stillbirth or an abnormal placental examination after birth. The finding is clinically meaningful, yet it does not prove that Factor V Leiden caused the pregnancy complication. Several maternal, placental and fetal pathways may produce similar results.

For families in Australia, assessment commonly involves a general practitioner, obstetrician, maternal-fetal medicine specialist, haematologist and sometimes a pathologist. Care may be organised differently in metropolitan Melbourne, Sydney or Perth than in regional Queensland, the Northern Territory or Western Australia, where travel and access to specialist ultrasound services can affect timing. A careful plan should account for both medical risk and the realities of pregnancy, work, transport and birth.

What the inherited variant changes

Factor V Leiden is most commonly discussed as a heterozygous variant, meaning one copy of the gene is affected. A person with two affected copies has a higher tendency to clot, although actual risk still depends on age, previous thrombosis, family history, surgery, immobility, obesity, smoking, hormonal exposure and other medical conditions. A laboratory result should therefore be interpreted alongside the person’s story rather than treated as a diagnosis of inevitable complications.

Pregnancy itself creates a pro-thrombotic state. This helps limit bleeding at birth, but it also means that a carrier may face a greater risk of deep vein thrombosis or pulmonary embolism during pregnancy and the postpartum period. The six weeks after birth are particularly important, and risk may be further raised after caesarean birth, prolonged admission, infection or reduced mobility.

The genetic result does not automatically explain miscarriage or a placental lesion. Factor V Leiden is more strongly established as a risk factor for venous thrombosis than as a single, definitive cause of placental insufficiency. Other inherited or acquired thrombophilias, antiphospholipid syndrome, hypertension, diabetes, infection and abnormalities in placental implantation may be more relevant in a particular pregnancy.

How placental thrombosis affects pregnancy

The placenta acts as the exchange organ between pregnant person and fetus. Maternal blood enters spaces around the chorionic villi, while fetal blood travels through vessels within the villi. Clotting or vascular injury can reduce this exchange surface. When enough placental tissue is affected, the fetus may receive less oxygen and fewer nutrients, sometimes leading to slowed growth or evidence of placental insufficiency.

A small placental infarct can be an incidental finding, particularly near the edge of the placenta. Larger or multiple infarcts are more concerning when they match clinical features such as early-onset fetal growth restriction, abnormal umbilical artery Doppler studies, recurrent pregnancy loss or hypertensive disease. Pathology reports often describe the size, location and age of lesions, but these findings must be combined with antenatal records and neonatal outcomes.

The placental pathology guide provides useful context for understanding how macroscopic and microscopic findings relate to clinical events. A report may mention maternal vascular malperfusion, fetal vascular malperfusion, intervillous thrombus or infarction; these terms describe patterns, not necessarily one identifiable cause.

Recognising clinical patterns

There may be no symptoms from a placental clot during pregnancy. Instead, clinicians may identify a pattern through routine care: fundal height measuring smaller than expected, reduced fetal growth on ultrasound, abnormal Doppler flow, high blood pressure, protein in the urine or changes in fetal movements. Some pregnancies remain uncomplicated even when Factor V Leiden is present.

Symptoms of a maternal venous clot require urgent attention. One-sided leg swelling, warmth or pain can indicate deep vein thrombosis. Sudden breathlessness, chest pain, coughing blood, collapse or a rapid heartbeat may indicate pulmonary embolism. In Australia, emergency assessment should be sought by calling Triple Zero (000), rather than waiting for a routine antenatal appointment.

Placental dysfunction can also overlap with infection, fetal genetic conditions and other causes of poor growth. Fever, uterine tenderness, offensive vaginal discharge or maternal deterioration should prompt assessment for infection. Resources covering neonatal sepsis management are especially relevant when a newborn is unwell, although neonatal sepsis and maternal thrombophilia are separate clinical problems that should not be conflated.

Testing and diagnosis in Australia

Factor V Leiden testing is usually considered after a personal history of venous thromboembolism, a strong family history, thrombosis at an unusually young age or a specialist-led assessment of recurrent pregnancy complications. Testing is not routinely required for every pregnant person or every case of miscarriage. The result may affect decisions about anticoagulation, future oestrogen exposure and planning around surgery or prolonged immobility.

Blood tests for thrombophilia can be difficult to interpret during pregnancy or while taking anticoagulants. Some tests are influenced by pregnancy-related changes, acute illness or recent thrombosis. A haematologist may recommend testing at a more reliable time, and genetic testing for Factor V Leiden is not altered by pregnancy. Patients should not stop prescribed anticoagulants to obtain a test without medical instruction.

Ultrasound surveillance may include fetal growth measurements, amniotic fluid assessment, placental appearance and Doppler studies of the umbilical artery or other vessels. The schedule is individualised according to prior outcomes, blood pressure, symptoms and findings. In Australia, public hospital care is generally covered through the Medicare system, while private patients may encounter different referral pathways, out-of-pocket costs and waiting times. Rural families may need coordinated telehealth, travel assistance or appointments grouped on the same day.

After delivery, placental examination can be valuable following stillbirth, severe fetal growth restriction, significant pre-eclampsia, suspected infection or an unusual neonatal course. The report should be reviewed with the obstetric team, and families can request an explanation of unfamiliar pathology terms.

Treatment across pregnancy and birth

Low-molecular-weight heparin is the anticoagulant most often considered when pregnancy-related thrombosis prevention is indicated. It does not cross the placenta and is commonly administered by subcutaneous injection. Whether it is needed, and at what dose, depends on factors such as previous thrombosis, homozygous or heterozygous status, family history and additional risk factors. A carrier with no personal clotting history may not require the same treatment as someone who has had a pulmonary embolism.

Aspirin may be recommended in selected pregnancies at increased risk of pre-eclampsia or placental-mediated complications, but it is not a universal treatment for Factor V Leiden. Anticoagulants and antiplatelet medicines work differently, and neither should be started, stopped or adjusted without the prescribing clinician. Australian care may follow local hospital protocols alongside guidance from bodies such as RANZCOG and specialist haematology services.

Planning for labour, epidural analgesia and caesarean birth requires communication about the last anticoagulant dose. Timing matters because neuraxial anaesthesia carries a rare but serious bleeding risk if anticoagulation is active. The maternity team should provide a written plan covering injections near the expected birth, induction, unplanned labour and the postnatal restart schedule.

Postpartum prevention deserves equal attention. A person may need anticoagulation after birth, particularly after caesarean delivery or when other risk factors are present. Safe movement, hydration, avoiding unnecessary prolonged sitting and recognising clot symptoms are practical measures, but they do not replace prescribed prophylaxis. Long car journeys between regional towns, hot weather and the routine of caring for a newborn can make regular medication and follow-up harder, so discharge planning should be specific and realistic.

Turning evidence into safer care

The most useful approach is a joined-up review of the maternal history, laboratory results, antenatal ultrasound findings, birth events and placental report. A previous stillbirth or growth-restricted pregnancy should be discussed before conception where possible. Pre-pregnancy counselling can clarify whether testing is useful, identify blood pressure or diabetes risks, review medicines and create a plan for early antenatal care.

Families should receive clear information about warning symptoms, injection technique, appointment timing and who to contact after hours. Clinicians can improve safety by documenting the Factor V Leiden status, prior thrombosis history and anticoagulation plan in a location visible to the maternity, anaesthetic and postnatal teams. This is particularly helpful when care moves between a local hospital and a tertiary centre in a capital city.

A diagnosis should guide proportionate care rather than create fear. Factor V Leiden is one part of a complex placental and maternal circulation story, and placental thrombosis is a finding that needs clinical context. Ask the treating team to explain the individual risk assessment, monitoring schedule and birth plan, and arrange timely review for any new leg swelling, chest symptoms, severe headache, bleeding, reduced fetal movements or sudden deterioration.